Valuation: Nuo Therapeutics, Inc.

Market Cap 48.41M 42.05M 39.05M 36.01M 67.83M 4.62B 69.06M 462M 181M 2.3B 182M 178M 7.72B P/E 2024
-27.4x
P/E 2025 -37.1x
Enterprise Value 48.46M 42.09M 39.09M 36.05M 67.9M 4.63B 69.13M 463M 181M 2.3B 182M 178M 7.73B EV / Sales 2024
47,922,901x
EV / Sales 2025 28,658,774x
Free-Float
42.1%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 63 2016-01-07
Chief Operating Officer 60 2014-03-29
Director TitleAgeSince
Director/Board Member 69 2009-01-29
Chairman 63 2012-02-06
Director/Board Member 67 2016-05-04
Change 5-day change 1-year change 3-year change Capi.($)
-16.66%-.--% - - 48.41M
-0.81%-0.33%+27.15%+81.12% 55.23B
+2.30%-5.02%+28.53%+67.18% 53.75B
-0.11%+0.86%-15.63%-13.56% 23.48B
-1.58%-5.51%-3.51%+375.36% 22B
+2.49%-0.92%+20.31%-12.15% 19.78B
+0.23%-1.68%+28.49%-33.73% 17.44B
+0.58%-5.88%+16.30%+540.37% 14.66B
+1.16%+0.58%+51.87%+181.96% 14.07B
-5.09%-10.87%+153.11%+272.20% 13.02B
Average -1.74%-1.55%+34.07%+162.08% 25.94B
Weighted average by Cap. +0.24%-0.44%+27.63%+125.20%

Financials

2024 2025
Net sales 1.37 1.19 1.1 1.02 1.91 130.33 1.95 13.04 5.1 64.73 5.13 5.01 217.68 3.31 2.88 2.67 2.46 4.64 316.34 4.73 31.64 12.39 157.11 12.44 12.17 528.35
Net income -2.32M -2.02M -1.87M -1.73M -3.26M -222M -3.31M -22.19M -8.69M -110M -8.73M -8.54M -371M -2.51M -2.18M -2.03M -1.87M -3.52M -240M -3.58M -23.99M -9.39M -119M -9.43M -9.23M -401M
Net Debt -120K -104K -96.4K -88.9K -167K -11.41M -170K -1.14M -447K -5.67M -449K -439K -19.06M 48.4K 42.04K 39.04K 36K 67.82K 4.62M 69.05K 462K 181K 2.29M 182K 178K 7.72M
Logo Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. is a commercial stage medical device company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. It has commercialized cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company's product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. Its commercial offering consists of a point of care technology for the separation of autologous blood to produce a platelet-based therapy for use in the chronic wound care market. The Aurix System produces a platelet-rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. The Aurix PRP comprises a natural, endogenous complement of protein and non-protein signal molecules that are believed to contribute to effective healing.
Employees
-